Guardian Pharmacy Services Reports Preliminary Q4 and Full-Year 2024 Results, Provides 2025 Guidance Guardian Pharmacy Services, Inc. (“Guardian” or the “Company”) (NYSE: GRDN), one of the largest long-term care (LTC) pharmacy services companies in the United States, has announced its…
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth Wedgewood, the nation’s largest provider of compounded veterinary medications and pharmacy solutions, has appointed Jessica Knopp-Gwynne as Chief Revenue Officer (CRO). With extensive experience in revenue growth, commercial strategy,…
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day Arrowhead Pharmaceuticals Expands “We’ll Get There Soon” Campaign with New Resources for Familial Chylomicronemia Syndrome on Rare Disease Day Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is marking Rare Disease Day with…
Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the expansion…
Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, has officially launched its business with a $5M seed investment from PacBridge Capital Partners (“PacBridge”).…
Bruker Expands Proteomics Capabilities with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in 4D-Proteomics™ performance, software, and applications to enhance biological insights. These new developments aim to refine…
Samsung Bioepis Co., Ltd. has announced the official U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), expanding treatment options for patients with inflammatory conditions. This development marks a significant milestone in the biosimilars market and further solidifies Samsung…
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort Following Successful Initial Results Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative CD19-targeted ARTEMIS® T-cell therapies for the treatment of cancer…
Go Reply and Sprint Reply Automate Clinical Study Report Generation for Dr. Willmar Schwabe Using AI In a groundbreaking collaboration, Go Reply, a leading Google Cloud Premier Partner, and Sprint Reply, the Reply Group’s expert in strategic consulting and digital…
New International Guidelines Released for the Treatment of Candida Fungal Infections A groundbreaking global guideline for the diagnosis and treatment of Candida infections has been published in The Lancet Infectious Diseases. This comprehensive guideline establishes new standards for the management…
Alzamend Neuro Advances Alzheimer’s and Psychiatric Disorder Research with Tesla-Developed Head Coil for Phase II Trials Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and psychiatric disorders, has announced the completion…
Stablepharma Secures Prestigious €2.5 Million EIC Accelerator Grant, Recognised Among Europe’s Leading Innovators UK-based biotechnology company Stablepharma Ltd has secured €2.5 million in funding from the highly competitive European Innovation Council (EIC) Accelerator program. This significant achievement highlights the company’s…